4 aug 2021
CPhI South East Asia 2021
Jiangsu Hengrui Medicine Co., Ltd

Jiangsu Hengrui Medicine Co., Ltd

Exhibitor at CPhI South East Asia 2021 stand stand 6.923

About us

     Hengrui Medicine is a leading pharmaceutical company based in China with a focus on research, development, manufacturing, and commercialization of innovative and high-quality healthcare products. In 1997, it was restructured into a joint-stock company. In 2000 Hengrui was listed on Shanghai Stock Exchange under stock code 600276. The company ranks top 30 worldwide in pharmaceuticals industry by a market capitalization of over 55 billion USD, and is home to more than 21,900 employees worldwide. Hengrui stands out as a front-runner in cancer drugs, contrast agents, and surgical medicines. Hengrui fully owns 8 manufacturing facilities for small and large molecules as well as medical devices. All facilities are approved and audited by NMPA, most also approved by US FDA, EDQM, TGA, and PMDA. We have 11 R&D centers where over 3,000 research staff work on hundreds of therapeutic candidates, many of which may become first-in-class or best-in-class products. Hengrui conducts most of its clinical trials using in-house capabilities that cover medical, trial operations, data management, statistics, and regulatory. This allows us to better control speed and quality. Embracing the spirit of “Honesty and Trustworthiness, Quality First” as a business principle, Hengrui leads the Chinese markets for anti-cancer drugs, surgical anesthetics, specialized infusions, and contrast agents. To date, Hengrui has 10+ products approved in Europe, US, and Japan, covering injectables, oral formulations, and inhalational anesthetics, and has achieved remarkable sales in those markets. Pursuing the concept of “Excelling in Science, Enhancing Life”, Hengrui sees its future as a Chinese multi-national pharmaceutical corporation, and continuously strives for innovation, progress, and achievement of new breakthrough in the healthcare industry. Contact: Mr Dong Wei
Email: [email protected], [email protected]

Specs about this supplier

Sales markets Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)
Affiliated categories: APIs (Active Pharmaceutical Ingredients) |Finished Dosage Forms |Injectables More

Products featured at CPhI South East Asia 2021

Categories affiliated with Jiangsu Hengrui Medicine Co., Ltd

Jiangsu Hengrui Medicine Co., Ltd

Event information

CPhI South East Asia 2021

4 - 6 August 2021 Hall 7-8, IMPACT, Muang Thong Thani, Thailand Visit us at stand 6.923